Skip to main content
S&P 5007,650.50+0.17%DOW51,682.64-0.18%NASDAQ26,522.54+0.39%BTC$81,273.00+6.27%ETH$2,618.91+7.14%GOLD$4,415.90+0.37%OIL$95.47-1.81%
Smart Investors Daily
SA

NASDAQ · SABSW

SAB Biotherapeutics, Inc.

Healthcare · Biotechnology

$0.01

Down-$0.00 (-7.89%)

Updated Sep 20, 2026, 8:17 AM

SID Score

2.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
239.91K
P/E ratio
2.04
Dividend yield
0.00%
52-week range
$0.00 – $0.20
Volume
3.06K
Avg. volume
27.05K

Price performance

SABSW price history

1M range · 18 trading sessions · Daily adjusted prices

SABSW closed at $0.01 after 18 trading sessions, down 53.49% for the selected period.

Last close
$0.01
Period change
-53.49%
Period low
$0.01
Period high
$0.03
Daily close
View OHLC price history
SABSW OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 18, 2026$0.0151$0.0151$0.014$0.0143.06K
Sep 17, 2026$0.014$0.0163$0.014$0.015231.63K
Sep 16, 2026$0.014$0.014$0.014$0.014306
Sep 15, 2026$0.0141$0.0141$0.014$0.0146.41K
Sep 14, 2026$0.0209$0.0209$0.014$0.014267.79K
Sep 11, 2026$0.0178$0.0395$0.0178$0.01947.6K
Sep 10, 2026$0.0181$0.0181$0.014$0.01430.13K
Sep 9, 2026$0.0183$0.0183$0.0182$0.01822.5K
Sep 8, 2026$0.0259$0.0436$0.0182$0.0182297.79K
Sep 4, 2026$0.0235$0.0236$0.0235$0.0236611
Sep 3, 2026$0.0235$0.0235$0.0235$0.02351.43K
Sep 2, 2026$0.0237$0.0237$0.0235$0.02351.18K
Sep 1, 2026$0.0237$0.0266$0.0237$0.02371.41K
Aug 31, 2026$0.0204$0.0297$0.0204$0.023717.64K
Aug 28, 2026$0.0258$0.0258$0.0258$0.02589.94K
Aug 27, 2026$0.0276$0.0276$0.0252$0.025415.54K
Aug 25, 2026$0.0396$0.0399$0.0251$0.027550.32K
Aug 24, 2026$0.027$0.09$0.026$0.03011.26M

Latest SABSW news

The latest Smart Investors Daily articles mentioning SABSW.

Stock researchCompany · Overview

SABSW research

Overview

Company profile and research snapshot.

Company profile

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 13, 2025

SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights

Initiated registrational Phase 2b SAFEGUARD trial of SAB-142 in new-onset, Stage 3 autoimmune T1D patientsMultiple SAFEGUARD trial sites activated; on-track to dose first patient by year-endRecent data presented at EASD and IPSAD provide further validation for SAB-142 as a novel, potentially best-in-class, disease-modifying, immunotherapeutic approach to redefine treatment of Stage 3 T1DStrong cash position with operational runway through 2028, enabling completion of registrational Phase 2b SAFE

Benzinga · Sep 16, 2025

SILQFi Launches Omni Following Acquisition of OXO

SILQFi has launched Omni, a new financial platform for small businesses, after acquiring OXO. The platform integrates point-of-sale, procurement, payments, and credit access to streamline merchant workflows and improve capital access in Saudi Arabia.

GlobeNewswire Inc. · May 9, 2025

SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates

SAB BIO, a clinical-stage biopharmaceutical company, reported financial results for Q1 2025. The company made progress on its type 1 diabetes program, including positive Phase 1 data for its lead candidate SAB-142. SAB BIO also achieved manufacturing milestones and saw a decrease in R&D and G&A expenses.

GlobeNewswire Inc. · Jan 31, 2025

SAB BIO to Participate in Upcoming Investor Conferences

SAB BIO, a clinical-stage biopharmaceutical company, announced its participation in upcoming investor conferences to discuss its lead asset, SAB-142, which targets type 1 diabetes with a disease-modifying approach.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By